146 related articles for article (PubMed ID: 37916393)
1. A key to engineering natural killer cells to attack acute myeloid leukemia.
Masamoto Y; Kurokawa M
Haematologica; 2024 Apr; 109(4):1032-1034. PubMed ID: 37916393
[No Abstract] [Full Text] [Related]
2. [Myeloid/natural killer cell precursor and myeloid/natural killer cell acute leukemia].
Ni M; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):525-9. PubMed ID: 24763036
[TBL] [Abstract][Full Text] [Related]
3. Do educated natural killer cells make the grade in treating acute myeloid leukemia?
Chakraverty R
Haematologica; 2012 Nov; 97(11):1617. PubMed ID: 23125241
[No Abstract] [Full Text] [Related]
4. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Cell-Based Immunotherapy in Acute Myeloid Leukemia: Lessons for the Future.
Muntasell A; López-Botet M
Clin Cancer Res; 2016 Apr; 22(8):1831-3. PubMed ID: 26903071
[TBL] [Abstract][Full Text] [Related]
6. Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells.
Langenkamp U; Siegler U; Jörger S; Diermayr S; Gratwohl A; Kalberer CP; Wodnar-Filipowicz A
Haematologica; 2009 Nov; 94(11):1590-4. PubMed ID: 19608675
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time?
Verneris MR; Grupp SA
J Clin Oncol; 2010 Feb; 28(6):909-10. PubMed ID: 20085932
[No Abstract] [Full Text] [Related]
8. Immunotherapy with natural killer cells: a possible approach for the treatment of Acute Myeloid Leukemia also in Brazil.
Silla L
Rev Assoc Med Bras (1992); 2016 Oct; 62 Suppl 1():23-24. PubMed ID: 27982314
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J; Niu T
J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
[TBL] [Abstract][Full Text] [Related]
10. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1.
Szczepanski MJ; Szajnik M; Welsh A; Whiteside TL; Boyiadzis M
Haematologica; 2011 Sep; 96(9):1302-9. PubMed ID: 21606166
[TBL] [Abstract][Full Text] [Related]
11. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
12. Myeloid/natural killer (NK) cell precursor acute leukemia as a distinct leukemia type.
Nishimura A; Yokoyama K; Naruto T; Yamagishi C; Imamura T; Nakazono H; Kimura S; Ito M; Sagisaka M; Tanaka Y; Piao J; Namikawa Y; Yanagimachi M; Isoda T; Kanai A; Matsui H; Isobe T; Sato-Otsubo A; Higuchi N; Takada A; Okuno H; Saito S; Karakawa S; Kobayashi S; Hasegawa D; Fujisaki H; Hasegawa D; Koike K; Koike T; Rai S; Umeda K; Sano H; Sekinaka Y; Ogawa A; Kinoshita A; Shiba N; Miki M; Kimura F; Nakayama H; Nakazawa Y; Taga T; Taki T; Adachi S; Manabe A; Koh K; Ishida Y; Takita J; Ishikawa F; Goto H; Morio T; Mizutani S; Tojo A; Takagi M
Sci Adv; 2023 Dec; 9(50):eadj4407. PubMed ID: 38091391
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemia.
Lemoli RM; Parisi S; Curti A
Exp Hematol; 2017 Jan; 45():10-16. PubMed ID: 27826123
[TBL] [Abstract][Full Text] [Related]
17. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
18. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
[TBL] [Abstract][Full Text] [Related]
19. Myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as FAB-M3 acute myeloid leukemia.
Paietta E; Gallagher RE; Wiernik PH
Blood; 1994 Oct; 84(8):2824-5. PubMed ID: 7522645
[No Abstract] [Full Text] [Related]
20. Modifying the biological response to acute myeloid leukemia I. BCG, allogeneic leukemic cells and spontaneous cytotoxicity.
Arends-Merino A; Sjögren AM; Reizenstein P
Anticancer Res; 1983; 3(4):239-41. PubMed ID: 6576728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
